Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ESRRA | P11474 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991630 | 0.92 | MRGPRX4 (0.31) | MRGPRX4 | |
| SCHEMBL13044884 | 0.92 | ALDH1A1 (0.31) | ALDH1A1HPGDTSHRHSD17B10PTGDR2 | |
| SCHEMBL13946760 | 0.92 | CYP3A4 (0.31) | ALDH1A1HPGDTSHRHSD17B10PTGDR2 | |
| SCHEMBL13107303 | 0.88 | ESRRA (0.34) | MRGPRX4PTGDR2BRAFKDRESRRA | |
| SCHEMBL13044701 | 0.88 | ALDH1A1 (0.33) | ALDH1A1HPGDTSHRHSD17B10TAS1R3 | |
| SCHEMBL13044704 | 0.88 | SCN9A (0.35) | BRAFKDR | |
| SCHEMBL13044881 | 0.87 | ESRRA (0.33) | ALDH1A1HPGDTSHRHSD17B10TAS1R3 | |
| SCHEMBL13947535 | 0.87 | ESRRA (0.33) | ALDH1A1HPGDTSHRHSD17B10TAS1R3 | |
| SCHEMBL13044886 | 0.85 | ESRRA (0.33) | ALDH1A1HPGDTSHRHSD17B10TAS1R3 | |
| SCHEMBL11991628 | 0.85 | TAS1R3 (0.30) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | MRGPRX4 3373/4885ALDH1A1 1257/4885HPGD 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.